Is Cerus (CERs) a good growth stock to buy?
Growth stocks tend to perform well when the economy starts to pick up. Nissan Motor (NSANY), Arko Corp. (ARKO), Arcos Dorados (ARCO) and Cerus (CERS) look well-poised to grow. How Much Upside is Left in Cerus (CERS)?
Where can I buy shares of CERs?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Will Cerus Inc (CERS) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote “Outperform” if you believe CERS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
When will Cerus Corporation's first quarter 2022 financial results be released?
CONCORD, Calif.-- (BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock m...
Is CERS stock a buy?
The consensus among 4 Wall Street analysts covering (NASDAQ: CERS) stock is to Strong Buy CERS stock.
Is Cerus publicly traded?
Cerus Corporation is currently listed on NASDAQ under CERS.
How has Cerus' stock price performed in 2022?
Cerus' stock was trading at $6.81 at the beginning of 2022. Since then, CERS stock has decreased by 23.1% and is now trading at $5.24. View the be...
When is Cerus' next earnings date?
Cerus is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Cerus .
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) released its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.07) earnings per share (EPS) fo...
What guidance has Cerus issued on next quarter's earnings?
Cerus updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of for the period. The company issued revenue g...
Who are Cerus' key executives?
Cerus' management team includes the following people: Mr. William M. Greenman , Pres, CEO & Director (Age 55, Pay $1.25M) Dr. Laurence M. Corash...
What is William M. (Obi) Greenman's approval rating as Cerus' CEO?
15 employees have rated Cerus CEO William M. (Obi) Greenman on Glassdoor.com . William M. (Obi) Greenman has an approval rating of 35% among Cerus...
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include West Pharmaceutical Services (WST) , Align Technology (ALGN) , Cooper Companies (COO) , DENTSP...
What other stocks do shareholders of Cerus own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD) , SCYNEXIS (SC...
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
When will Cerus release its earnings?
How much does Cerus make?
Cerus is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021. View our earnings forecast for Cerus.
What is Cerus Corporation?
How much money does Cerus make? Cerus has a market capitalization of $852.43 million and generates $91.92 million in revenue each year . The biotechnology company earns $-59,860,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.
What is the Cerus system?
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
When will Cerus release its second quarter results?
Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
What is Cerus Corporation?
Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020. CONCORD, Calif.-- (BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock... 11 months ago - Business Wire.
When will Cerus release its results?
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
What is the focus of Wall Street?
Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020. CONCORD, Calif.-- (BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the sto...
NASDAQ
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Environmental, Social, and Governance Rating
The Company develops and commercializes novel, proprietary products and technologies within the fields of blood safety and immunotherapy that provides safer and more medical options to patients in areas of unmet medical need.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
